Chimerix (NASDAQ:CMRX) Rating Increased to Hold at Zacks Investment Research

Chimerix (NASDAQ:CMRX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Wednesday, Zacks.com reports.

According to Zacks, “Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina. “

Other analysts have also recently issued research reports about the company. HC Wainwright lifted their price objective on Chimerix from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Thursday, August 1st. ValuEngine raised Chimerix from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $4.00.

CMRX opened at $2.18 on Wednesday. The stock has a market cap of $129.28 million, a price-to-earnings ratio of -1.52 and a beta of 1.34. Chimerix has a 1 year low of $1.74 and a 1 year high of $4.40. The stock has a fifty day moving average price of $2.65 and a 200 day moving average price of $2.87.

Chimerix (NASDAQ:CMRX) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.18). The firm had revenue of $1.44 million for the quarter, compared to analyst estimates of $2.30 million. Chimerix had a negative net margin of 729.02% and a negative return on equity of 38.70%. As a group, research analysts forecast that Chimerix will post -1.1 earnings per share for the current year.

Several large investors have recently made changes to their positions in CMRX. SG Americas Securities LLC lifted its position in shares of Chimerix by 105.4% in the first quarter. SG Americas Securities LLC now owns 20,590 shares of the biopharmaceutical company’s stock worth $43,000 after buying an additional 10,567 shares during the last quarter. Quantitative Systematic Strategies LLC acquired a new stake in shares of Chimerix in the second quarter worth about $67,000. Susquehanna International Group LLP acquired a new stake in shares of Chimerix in the second quarter worth about $92,000. Prudential Financial Inc. acquired a new stake in shares of Chimerix in the second quarter worth about $104,000. Finally, Marshall Wace LLP acquired a new stake in shares of Chimerix in the first quarter worth about $166,000. 61.96% of the stock is owned by institutional investors.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.

Featured Story: What is a closed-end mutual fund (CEF)?

Get a free copy of the Zacks research report on Chimerix (CMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.